Clinical trials: Hepatic Neoplasm
Hepatocellular Carcinoma
A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC
The purpose of this study is to evaluate the effect of the anti-programmed death 1 (PD-1) agent nivolumab following selective internal radiation therapy (SIRT) for patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NASIR-HCC (NCT03380130)
- Testing
- Nivolumab, SIR-Spheres
- Where
- 9 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Colorectal Cancer, Liver Tumor
Effect of Target Therapy on Patients Undergoing Synchronic Hepatectomy for Colorectal Liver Metastases
The aim of this study is to explore whether target therapy in combination with chemotherapy as treatment could improve survival or tumor response in patients undergoing Synchronic Hepatectomy for Colorectal Liver Metastases.
- Trial name
- NCT01677728
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xu jianmin
Hepatocellular Carcinoma
Effects of EPA Supplementation on Patients With Unresectable Hepatocellular Carcinoma.
Dietary intervention with eicosapentaenoic acid combined with chemotherapy may shift inflammatory mediators toward resolution in non-resectable hepatocarcinoma and help to preserve muscle mass.
- Trial name
- NCT07664007
- Testing
- Eicosapentaenoic acid oral lipidic emulsion, Pacebo oral lipidic emulsion
- Where
- Spain
- Volunteers
- 18 people
- Sponsor
- Instituto de Investigación Sanitaria Aragón
Hepatocellular Carcinoma
Combined Ipsilateral Liver Lobe Devascularization and Alcohol Treatment of the Large Hepatocellular Carcinoma
Assessment of the long-term outcome of combined ipsilateral liver lobe devascularization (ILAD) and alcohol injection of the large hepatocellular carcinoma (HCC): single center non-randomized trial.
- Trial name
- NCT03138044
- Testing
- Combined Treatment
- Where
- Sudan
- Volunteers
- 12 people
- Sponsor
- The National Ribat University
Liver Cancer
Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Carcinoma
The purpose of this study is to evaluate the safety and efficacy of nano drug（Gemzar® mix with Compound Glycyrrhizin Injection） interventional therapy using digital subtraction angiography（DSA） for liver cancer.
- Trial name
- NCT02449109
- Testing
- interventional therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Colorectal Cancer Metastatic
Pilot Study to Assess the Safety and Pharmacokinetics of 70-150μm Drug Eluting Beads Loaded With Irinotecan (DEBIRI).
Background Hepatic metastases of colorectal cancer (MCC) is quite common and is a major source of morbidity and mortality. There has been evidence to show that hepatic arterial chemoembolisation using DC beads (drug eluting…
- Trial name
- NCT02350400
- Testing
- DEBIRI
- Where
- 2 sites in Singapore
- Volunteers
- 5 people
- Sponsor
- Singapore General Hospital
Hepatocarcinoma
Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation
To evaluate the efficacy and safety of Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma following Local Ablation
- Trial name
- NCT03356236
- Where
- 17 sites in China
- Volunteers
- 828 people
- Sponsor
- Yue Han
Hepatocellular Carcinoma
CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma
This study is designed to determine the safety and efficacy of CAR-GPC3 T cells in patients with relapsed or refractory hepatocellular carcinoma.
- Trial name
- NCT03146234
- Testing
- CAR-GPC3 T cells
- Where
- China
- Volunteers
- 7 people
- Sponsor
- RenJi Hospital
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
RATIONALE: Drugs used in chemotherapy such as gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00059865
- Testing
- gemcitabine hydrochloride, pemetrexed disodium
- Where
- 41 sites in United States
- Volunteers
- 68 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Carcinoma, Hepatocellular, Liver Neoplasms
HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
This study intends to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and Sintilimab for patients hepatocellular carcinoma and portal vein…
- Conditions
- Carcinoma, Hepatocellular, Liver Neoplasms, Sintilimab, Portal Vein Tumor Thrombus
- Trial name
- NCT04618367
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Liver Cancer
Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00941967
- Testing
- gemcitabine hydrochloride, oxaliplatin, sorafenib tosylate
- Where
- France
- Volunteers
- 78 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Liver Cancer (Locally Advanced or Metastatic), Liver Cancer Adult
Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)
This clinical trial will test whether a short infusion of a drug called angiotensin II (AT-II) can make a liver cancer treatment work better.
- Trial name
- RADIANT (NCT07312292)
- Testing
- Angiotensin II (Giapreza®), Yttrium-90 radioembolization
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Niek Wijnen
Unresectable Hepatocellular Carcinoma
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
The efficacy and safety of HAIC combined with tyrosine kinase inhibitor and immunotherapy have been proved by the clinical research.
- Trial name
- NCT05135364
- Testing
- Camrelizumab, HAIC, TKI
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Yue Han
Cancer, Solid Tumor
Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
This study aims to assess biomarkers and their related polymorphisms in the context of cancer-associated thromboembolism, with a particular focus on their interaction with the immune system.
- Conditions
- Cancer, Solid Tumor, Thromboembolism, Cardiovascular Diseases
- Trial name
- CAT_PB (NCT06065592)
- Testing
- Palbociclib, Rivaroxaban, SNP
- Where
- 2 sites in Lebanon
- Volunteers
- 500 people
- Sponsor
- Lebanese University
Hepatocellular Carcinoma
Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of Cadonilimab(AK104) in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment…
- Trial name
- NCT06406634
- Testing
- Cadonilimab, Lenvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hunan Cancer Hospital
Hepatocellular Carcinoma
HR Combined With FOLFOX4 for HCC With PVTT
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most frequent cause of cancer death worldwide. Hepatic resection (HR) is the conventional ''curative'' treatment for HCC.
- Trial name
- NCT02452853
- Testing
- HR, FOLFOX4
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Unresectable Hepatocellular Carcinoma
Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers…
- Trial name
- TACE (NCT02006030)
- Testing
- ADI-PEG 20, Transarterial chemoembolization
- Where
- 4 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- Polaris Group
Subjects With Resectable and Localized Gastric Cancer, Subjects With Resectable Esophageal Cancer or Liver Cancer
Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers
This is a phase II, open-label, prospective single-centered study. Subjects who meet the inclusion/exclusion criteria will be allocated to appropriate cohorts: 1) gastric cancer, 2) esophageal cancer and 3) hepatocellular…
- Conditions
- Subjects With Resectable and Localized Gastric Cancer, Subjects With Resectable Esophageal Cancer or Liver Cancer, Subjects With Resectable Liver Cancer
- Trial name
- NeoChance (NCT04196465)
- Testing
- IMC-001
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Asan Medical Center
Hepatocellular Cancer
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
This study evaluates the safety and efficacy of administering sorafenib concurrent with yttrium-90 radioembolization to patients with advanced hepatocellular cancer.
- Trial name
- NCT02288507
- Testing
- Sorafenib, yttrium-90 radioembolization
- Where
- United States
- Sponsor
- University of Hawaii
Hepatocellular Carcinoma, Radiotherapy
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
This is a single-center, single-arm, open-label study that includes patients meeting the inclusion criteria (liver-GTV volume < 700ml or estimated liver-GTV V5 < 300ml) with hepatocellular carcinoma with diffuse tumor thrombosis…
- Conditions
- Hepatocellular Carcinoma, Radiotherapy, Tislelizumab, Tumor Thrombosis
- Trial name
- NCT06233981
- Testing
- Moderate-dose Hypofractionated Intensity-modulated Radiotherapy, Tislelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.